Suchergebnisse - "Li, Chunze"

PubPharm (176)

1

Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2024

von Yip, V. | Saad, O. | Leipold, D. | +3

2

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Deng, R. | Gibiansky, L. | Lu, T. | +11

3

Patient, industry, and regulatory perspective on antibody-drug conjugates dose optimization

enthalten in: Clinical and translational science | 2024

von Hamed, S. | Li, C. | Liao, M. | +2

4

Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings

enthalten in: Advanced drug delivery reviews | 2024

von Liao, M. | Lu, D. | Lu, T. | +11

5

Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Chen, Y. | Ma, F. | Jones, N. | +3

6

Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization

enthalten in: Clinical and Translational Science | 2024

von Hamed, S. | Li, C. | Liao, M. | +2

7

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling

enthalten in: CPT: Pharmacometrics & Systems Pharmacology | 2024

von Chen, Y. | Ma, F. | Jones, N. | +3

8

Ethnic sensitivity assessment : Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX

enthalten in: Clinical and translational science | 2023

von Liao, M. | Deng, R. | Gibiansky, L. | +9

9

Correction : Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Bruno, R. | Marchand, M. | Yoshida, K. | +12

ErratumFor: Clin Cancer Res. 2023 Mar 14;29(6):1047-1055. - PMID 36595566

10

Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models

enthalten in: British journal of cancer | 2023

von Bruno, R. | Chanu, P. | Kågedal, M. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]